BRAF antibody
-
- Target See all BRAF Antibodies
- BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))
-
Reactivity
- Human
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- This BRAF antibody is un-conjugated
-
Application
- ELISA, Immunohistochemistry (IHC)
- Purpose
- BRAF Antibody
- Purification
- Ascitic fluid
- Immunogen
- Purified recombinant fragment of BRAF expressed in E. Coli.
- Clone
- 1H12F1
- Isotype
- IgG1
- Top Product
- Discover our top product BRAF Primary Antibody
-
-
- Application Notes
- ELISA: 1/10000
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Buffer
- Ascitic fluid containing 0.03 % sodium azide.
- Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C,-20 °C
- Storage Comment
- Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
-
-
Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma." in: Annals of surgery, Vol. 244, Issue 5, pp. 799-804, (2006) (PubMed).
: "The amino-terminal B-Raf-specific region mediates calcium-dependent homo- and hetero-dimerization of Raf." in: The EMBO journal, Vol. 25, Issue 15, pp. 3556-64, (2006) (PubMed).
: "Frequent involvement of ras-signalling pathways in both polypoid-type and flat-type early-stage colorectal cancers." in: Journal of experimental & clinical cancer research : CR, Vol. 25, Issue 2, pp. 235-42, (2006) (PubMed).
: "BRAF and NRAS mutations in spitzoid melanocytic lesions." in: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, Vol. 19, Issue 10, pp. 1324-32, (2006) (PubMed).
: "
-
Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma." in: Annals of surgery, Vol. 244, Issue 5, pp. 799-804, (2006) (PubMed).
-
- Target
- BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))
- Alternative Name
- BRAF (BRAF Products)
- Synonyms
- B-RAF1 antibody, BRAF1 antibody, NS7 antibody, RAFB1 antibody, C-RMIL antibody, RMIL antibody, B-Raf antibody, braf1 antibody, rafb1 antibody, b-raf1 antibody, sierrabraf antibody, BRAF antibody, 9930012E13Rik antibody, AA120551 antibody, AA387315 antibody, AA473386 antibody, B-raf antibody, Braf-2 antibody, Braf2 antibody, C230098H17 antibody, C87398 antibody, D6Ertd631e antibody, braf antibody, fc48g01 antibody, wu:fc48g01 antibody, B-Raf proto-oncogene, serine/threonine kinase antibody, B-Raf proto-oncogene, serine/threonine kinase S homeolog antibody, Braf transforming gene antibody, si:dkey-222f8.3 antibody, BRAF antibody, Braf antibody, braf.S antibody, braf antibody, si:dkey-222f8.3 antibody
- Background
-
Description: BRAF(V-raf murine sarcoma viral oncogene homolog B1 ) is the main effectors recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway. B-Raf contains three consensus Akt phosphorylationsites (Ser364, Ser428, and Thr439).B-Raf is a key regulatory molecule of the mitogen-activated protein kinase kinase (MEK),it has a long amino-terminal region,the region is essential for homo-dimerization of B-Raf and hetero-dimerization of B-Raf and c-Raf at the plasma membrane, followed by phosphorylation of Thr118 in the amino-terminal B-Raf-specific region. Notably, in calcium ionophore-stimulated HeLa cells, B-Raf could propagate signals to MEK under the basal level of GTP-Ras. Expression of Raf-B is highly restricted with highestlevels in the cerebrum and testes and defects in braf are involved in a wide range of cancers.The BRAF gene mutation is frequently detected in papillary thyroid carcinoma,melanocytic nevi,primary cutaneous melanomas and colorectal cancers.
Aliases: BRAF
- Gene ID
- 673
- HGNC
- 673
- UniProt
- P15056
- Pathways
- MAPK Signaling, RTK Signaling, Neurotrophin Signaling Pathway, Ribonucleoprotein Complex Subunit Organization, Hepatitis C, Autophagy
-